A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women
Abstract Objectives Different gonadotropin-releasing-hormone agonist (GnRH-a) formulations with different potency and associated side effects, therefore, different compliance and persistence of therapy. This study was to evaluate the difference of hormonal profile and side effects due to hypoestroge...
Gespeichert in:
Veröffentlicht in: | European journal of obstetrics & gynecology and reproductive biology 2014-12, Vol.183, p.164-168 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 168 |
---|---|
container_issue | |
container_start_page | 164 |
container_title | European journal of obstetrics & gynecology and reproductive biology |
container_volume | 183 |
creator | Li, Zheng Zhang, Hong yuan Zhu, Ying jun Hu, Yuan jing Qu, Peng peng |
description | Abstract Objectives Different gonadotropin-releasing-hormone agonist (GnRH-a) formulations with different potency and associated side effects, therefore, different compliance and persistence of therapy. This study was to evaluate the difference of hormonal profile and side effects due to hypoestrogenic status after treatment of leuprorelin and triptorelin in Chinese women with ovarian endometrioma after conservative surgical treatment. Study design A total of 302 women underwent laparoscopic excision of ovarian endometriomas with rASRM III and IV were enrolled in the study.Subjects were randomized into two groups with use of a random table. Twenty two patients dropped out during the study. Thus 142 patients had three doses of i.m. leuprorelin (group A) and 138 patients had three doses of i.m. triptorelin(group B) at 4 weeks intervals after surgical treatment. Menopausal symptoms were evalutaed using a questionnaire and serum sex hormonal levels were also measured during the follow-up. Results At week 4 after the treatment, most of the patients in leuprorelin group have no obvious side effects. After 9 weeks, bone pain, hot flashes and sweating, and irregular bleeding were the main side effects and showed no difference between the groups. Anxiety, depression, vaginal dryness, headache, and acne rates were all significantly higher in triptorelin group than in leuprorelin group. A significant difference in FSH ( p = 0.003), LH ( p = 0.026) and E2 ( p = 0.002) levels between the groups were observed after 21 days of the GnRHa treatment. The FSH ( p = 0.021) and E2 ( p = 0.033) levels remained higher in the leuprorelin group than the triptorelin group after six weeks of treatment, but the difference of LH( p = 0.917) level was no longer discernible. Conclusion Leuprorelin in down-regulating the pituitary-ovarian function was more moderate, and the hormonal levels decrease progressively and gradually, therefore, with lower rate of menopausal symptoms. Leuprorelin acetate maybe better tolerated than triptorelin. |
doi_str_mv | 10.1016/j.ejogrb.2014.10.022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687675926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0301211514005466</els_id><sourcerecordid>1687675926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-3cade62ca8ed74a4d66678141e687de4512ac2bed05bfb6368c210b3a3c547973</originalsourceid><addsrcrecordid>eNqNksuO0zAUhiMEYjoDb4CQl2xSfIuTbpBGFTBII7EA1pZjn7QOTlzspKPyYrweJ7SwYAPeWD76zn8uv4viBaNrRpl63a-hj7vUrjllEkNryvmjYsWampe1quTjYkUFZSVnrLoqrnPuKR4hNk-LK15JxUTNV8WPW5LM6OLgv4MjeZrdidg4HEzy445MeyDZOyDQdWCnTBAl-5iGOJqAtJnmTGJHpuQPU0wQ_PgLCTAf0uXdxRDiw6Jm45ghHc3kj0CCwRox23jwluQ57SCdkE0kHrG2GQksXQEqx-wzQaHt3o-QgTxgeHxWPOlMyPD8ct8UX969_by9K-8_vv-wvb0vrazoVAprHChuTQOulkY6pVTdMMlANbUDWTFuLG_B0artWiVUYzmjrTDCVrLe1OKmeHXWxXm-zZAnPfhsIQQzQpyzZqij6mrD1X-goqKUy5oiKs-oxRXkBJ0-JD-YdNKM6sVd3euzu3pxd4miu5j28lJhbgdwf5J-24nAmzMAuJKjh6Sz9TBacD6hf9pF_68KfwtY9NBbE77CCXIf54TO4yw6c031p-WHLR-MSUqxCSV-Al_I0g0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1635002470</pqid></control><display><type>article</type><title>A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Li, Zheng ; Zhang, Hong yuan ; Zhu, Ying jun ; Hu, Yuan jing ; Qu, Peng peng</creator><creatorcontrib>Li, Zheng ; Zhang, Hong yuan ; Zhu, Ying jun ; Hu, Yuan jing ; Qu, Peng peng</creatorcontrib><description>Abstract Objectives Different gonadotropin-releasing-hormone agonist (GnRH-a) formulations with different potency and associated side effects, therefore, different compliance and persistence of therapy. This study was to evaluate the difference of hormonal profile and side effects due to hypoestrogenic status after treatment of leuprorelin and triptorelin in Chinese women with ovarian endometrioma after conservative surgical treatment. Study design A total of 302 women underwent laparoscopic excision of ovarian endometriomas with rASRM III and IV were enrolled in the study.Subjects were randomized into two groups with use of a random table. Twenty two patients dropped out during the study. Thus 142 patients had three doses of i.m. leuprorelin (group A) and 138 patients had three doses of i.m. triptorelin(group B) at 4 weeks intervals after surgical treatment. Menopausal symptoms were evalutaed using a questionnaire and serum sex hormonal levels were also measured during the follow-up. Results At week 4 after the treatment, most of the patients in leuprorelin group have no obvious side effects. After 9 weeks, bone pain, hot flashes and sweating, and irregular bleeding were the main side effects and showed no difference between the groups. Anxiety, depression, vaginal dryness, headache, and acne rates were all significantly higher in triptorelin group than in leuprorelin group. A significant difference in FSH ( p = 0.003), LH ( p = 0.026) and E2 ( p = 0.002) levels between the groups were observed after 21 days of the GnRHa treatment. The FSH ( p = 0.021) and E2 ( p = 0.033) levels remained higher in the leuprorelin group than the triptorelin group after six weeks of treatment, but the difference of LH( p = 0.917) level was no longer discernible. Conclusion Leuprorelin in down-regulating the pituitary-ovarian function was more moderate, and the hormonal levels decrease progressively and gradually, therefore, with lower rate of menopausal symptoms. Leuprorelin acetate maybe better tolerated than triptorelin.</description><identifier>ISSN: 0301-2115</identifier><identifier>EISSN: 1872-7654</identifier><identifier>DOI: 10.1016/j.ejogrb.2014.10.022</identifier><identifier>PMID: 25461372</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adolescent ; Adult ; Biomarkers - blood ; Chemotherapy, Adjuvant ; China ; Drug Administration Schedule ; Endometriosis - blood ; Endometriosis - drug therapy ; Endometriosis - surgery ; Female ; Follow-Up Studies ; Gonadotropin-releasing hormone ; Hormone Antagonists - adverse effects ; Hormone Antagonists - therapeutic use ; Hormones - blood ; Humans ; Laparoscopy ; Leuprolide - adverse effects ; Leuprolide - therapeutic use ; Leuprorelin ; Middle Aged ; Obstetrics and Gynecology ; Ovarian Diseases - blood ; Ovarian Diseases - drug therapy ; Ovarian Diseases - surgery ; Ovary endometriosis ; Single-Blind Method ; Treatment Outcome ; Triptorelin ; Triptorelin Pamoate - adverse effects ; Triptorelin Pamoate - therapeutic use ; Young Adult</subject><ispartof>European journal of obstetrics & gynecology and reproductive biology, 2014-12, Vol.183, p.164-168</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2014 Elsevier Ireland Ltd</rights><rights>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-3cade62ca8ed74a4d66678141e687de4512ac2bed05bfb6368c210b3a3c547973</citedby><cites>FETCH-LOGICAL-c450t-3cade62ca8ed74a4d66678141e687de4512ac2bed05bfb6368c210b3a3c547973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejogrb.2014.10.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25461372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Zhang, Hong yuan</creatorcontrib><creatorcontrib>Zhu, Ying jun</creatorcontrib><creatorcontrib>Hu, Yuan jing</creatorcontrib><creatorcontrib>Qu, Peng peng</creatorcontrib><title>A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women</title><title>European journal of obstetrics & gynecology and reproductive biology</title><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><description>Abstract Objectives Different gonadotropin-releasing-hormone agonist (GnRH-a) formulations with different potency and associated side effects, therefore, different compliance and persistence of therapy. This study was to evaluate the difference of hormonal profile and side effects due to hypoestrogenic status after treatment of leuprorelin and triptorelin in Chinese women with ovarian endometrioma after conservative surgical treatment. Study design A total of 302 women underwent laparoscopic excision of ovarian endometriomas with rASRM III and IV were enrolled in the study.Subjects were randomized into two groups with use of a random table. Twenty two patients dropped out during the study. Thus 142 patients had three doses of i.m. leuprorelin (group A) and 138 patients had three doses of i.m. triptorelin(group B) at 4 weeks intervals after surgical treatment. Menopausal symptoms were evalutaed using a questionnaire and serum sex hormonal levels were also measured during the follow-up. Results At week 4 after the treatment, most of the patients in leuprorelin group have no obvious side effects. After 9 weeks, bone pain, hot flashes and sweating, and irregular bleeding were the main side effects and showed no difference between the groups. Anxiety, depression, vaginal dryness, headache, and acne rates were all significantly higher in triptorelin group than in leuprorelin group. A significant difference in FSH ( p = 0.003), LH ( p = 0.026) and E2 ( p = 0.002) levels between the groups were observed after 21 days of the GnRHa treatment. The FSH ( p = 0.021) and E2 ( p = 0.033) levels remained higher in the leuprorelin group than the triptorelin group after six weeks of treatment, but the difference of LH( p = 0.917) level was no longer discernible. Conclusion Leuprorelin in down-regulating the pituitary-ovarian function was more moderate, and the hormonal levels decrease progressively and gradually, therefore, with lower rate of menopausal symptoms. Leuprorelin acetate maybe better tolerated than triptorelin.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>Chemotherapy, Adjuvant</subject><subject>China</subject><subject>Drug Administration Schedule</subject><subject>Endometriosis - blood</subject><subject>Endometriosis - drug therapy</subject><subject>Endometriosis - surgery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gonadotropin-releasing hormone</subject><subject>Hormone Antagonists - adverse effects</subject><subject>Hormone Antagonists - therapeutic use</subject><subject>Hormones - blood</subject><subject>Humans</subject><subject>Laparoscopy</subject><subject>Leuprolide - adverse effects</subject><subject>Leuprolide - therapeutic use</subject><subject>Leuprorelin</subject><subject>Middle Aged</subject><subject>Obstetrics and Gynecology</subject><subject>Ovarian Diseases - blood</subject><subject>Ovarian Diseases - drug therapy</subject><subject>Ovarian Diseases - surgery</subject><subject>Ovary endometriosis</subject><subject>Single-Blind Method</subject><subject>Treatment Outcome</subject><subject>Triptorelin</subject><subject>Triptorelin Pamoate - adverse effects</subject><subject>Triptorelin Pamoate - therapeutic use</subject><subject>Young Adult</subject><issn>0301-2115</issn><issn>1872-7654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNksuO0zAUhiMEYjoDb4CQl2xSfIuTbpBGFTBII7EA1pZjn7QOTlzspKPyYrweJ7SwYAPeWD76zn8uv4viBaNrRpl63a-hj7vUrjllEkNryvmjYsWampe1quTjYkUFZSVnrLoqrnPuKR4hNk-LK15JxUTNV8WPW5LM6OLgv4MjeZrdidg4HEzy445MeyDZOyDQdWCnTBAl-5iGOJqAtJnmTGJHpuQPU0wQ_PgLCTAf0uXdxRDiw6Jm45ghHc3kj0CCwRox23jwluQ57SCdkE0kHrG2GQksXQEqx-wzQaHt3o-QgTxgeHxWPOlMyPD8ct8UX969_by9K-8_vv-wvb0vrazoVAprHChuTQOulkY6pVTdMMlANbUDWTFuLG_B0artWiVUYzmjrTDCVrLe1OKmeHXWxXm-zZAnPfhsIQQzQpyzZqij6mrD1X-goqKUy5oiKs-oxRXkBJ0-JD-YdNKM6sVd3euzu3pxd4miu5j28lJhbgdwf5J-24nAmzMAuJKjh6Sz9TBacD6hf9pF_68KfwtY9NBbE77CCXIf54TO4yw6c031p-WHLR-MSUqxCSV-Al_I0g0</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Li, Zheng</creator><creator>Zhang, Hong yuan</creator><creator>Zhu, Ying jun</creator><creator>Hu, Yuan jing</creator><creator>Qu, Peng peng</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20141201</creationdate><title>A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women</title><author>Li, Zheng ; Zhang, Hong yuan ; Zhu, Ying jun ; Hu, Yuan jing ; Qu, Peng peng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-3cade62ca8ed74a4d66678141e687de4512ac2bed05bfb6368c210b3a3c547973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>Chemotherapy, Adjuvant</topic><topic>China</topic><topic>Drug Administration Schedule</topic><topic>Endometriosis - blood</topic><topic>Endometriosis - drug therapy</topic><topic>Endometriosis - surgery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gonadotropin-releasing hormone</topic><topic>Hormone Antagonists - adverse effects</topic><topic>Hormone Antagonists - therapeutic use</topic><topic>Hormones - blood</topic><topic>Humans</topic><topic>Laparoscopy</topic><topic>Leuprolide - adverse effects</topic><topic>Leuprolide - therapeutic use</topic><topic>Leuprorelin</topic><topic>Middle Aged</topic><topic>Obstetrics and Gynecology</topic><topic>Ovarian Diseases - blood</topic><topic>Ovarian Diseases - drug therapy</topic><topic>Ovarian Diseases - surgery</topic><topic>Ovary endometriosis</topic><topic>Single-Blind Method</topic><topic>Treatment Outcome</topic><topic>Triptorelin</topic><topic>Triptorelin Pamoate - adverse effects</topic><topic>Triptorelin Pamoate - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Zhang, Hong yuan</creatorcontrib><creatorcontrib>Zhu, Ying jun</creatorcontrib><creatorcontrib>Hu, Yuan jing</creatorcontrib><creatorcontrib>Qu, Peng peng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Zheng</au><au>Zhang, Hong yuan</au><au>Zhu, Ying jun</au><au>Hu, Yuan jing</au><au>Qu, Peng peng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women</atitle><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>183</volume><spage>164</spage><epage>168</epage><pages>164-168</pages><issn>0301-2115</issn><eissn>1872-7654</eissn><abstract>Abstract Objectives Different gonadotropin-releasing-hormone agonist (GnRH-a) formulations with different potency and associated side effects, therefore, different compliance and persistence of therapy. This study was to evaluate the difference of hormonal profile and side effects due to hypoestrogenic status after treatment of leuprorelin and triptorelin in Chinese women with ovarian endometrioma after conservative surgical treatment. Study design A total of 302 women underwent laparoscopic excision of ovarian endometriomas with rASRM III and IV were enrolled in the study.Subjects were randomized into two groups with use of a random table. Twenty two patients dropped out during the study. Thus 142 patients had three doses of i.m. leuprorelin (group A) and 138 patients had three doses of i.m. triptorelin(group B) at 4 weeks intervals after surgical treatment. Menopausal symptoms were evalutaed using a questionnaire and serum sex hormonal levels were also measured during the follow-up. Results At week 4 after the treatment, most of the patients in leuprorelin group have no obvious side effects. After 9 weeks, bone pain, hot flashes and sweating, and irregular bleeding were the main side effects and showed no difference between the groups. Anxiety, depression, vaginal dryness, headache, and acne rates were all significantly higher in triptorelin group than in leuprorelin group. A significant difference in FSH ( p = 0.003), LH ( p = 0.026) and E2 ( p = 0.002) levels between the groups were observed after 21 days of the GnRHa treatment. The FSH ( p = 0.021) and E2 ( p = 0.033) levels remained higher in the leuprorelin group than the triptorelin group after six weeks of treatment, but the difference of LH( p = 0.917) level was no longer discernible. Conclusion Leuprorelin in down-regulating the pituitary-ovarian function was more moderate, and the hormonal levels decrease progressively and gradually, therefore, with lower rate of menopausal symptoms. Leuprorelin acetate maybe better tolerated than triptorelin.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>25461372</pmid><doi>10.1016/j.ejogrb.2014.10.022</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0301-2115 |
ispartof | European journal of obstetrics & gynecology and reproductive biology, 2014-12, Vol.183, p.164-168 |
issn | 0301-2115 1872-7654 |
language | eng |
recordid | cdi_proquest_miscellaneous_1687675926 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Adolescent Adult Biomarkers - blood Chemotherapy, Adjuvant China Drug Administration Schedule Endometriosis - blood Endometriosis - drug therapy Endometriosis - surgery Female Follow-Up Studies Gonadotropin-releasing hormone Hormone Antagonists - adverse effects Hormone Antagonists - therapeutic use Hormones - blood Humans Laparoscopy Leuprolide - adverse effects Leuprolide - therapeutic use Leuprorelin Middle Aged Obstetrics and Gynecology Ovarian Diseases - blood Ovarian Diseases - drug therapy Ovarian Diseases - surgery Ovary endometriosis Single-Blind Method Treatment Outcome Triptorelin Triptorelin Pamoate - adverse effects Triptorelin Pamoate - therapeutic use Young Adult |
title | A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T16%3A34%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized%20study%20comparing%20the%20side%20effects%20and%20hormonal%20status%20of%20triptorelin%20and%20leuprorelin%20following%20conservative%20laparoscopic%20surgery%20for%20ovarian%20endometriosis%20in%20Chinese%20women&rft.jtitle=European%20journal%20of%20obstetrics%20&%20gynecology%20and%20reproductive%20biology&rft.au=Li,%20Zheng&rft.date=2014-12-01&rft.volume=183&rft.spage=164&rft.epage=168&rft.pages=164-168&rft.issn=0301-2115&rft.eissn=1872-7654&rft_id=info:doi/10.1016/j.ejogrb.2014.10.022&rft_dat=%3Cproquest_cross%3E1687675926%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1635002470&rft_id=info:pmid/25461372&rft_els_id=S0301211514005466&rfr_iscdi=true |